The US Government keeps an online database, at clinicaltrials.gov, of clinical research studies for Mesothelioma cancer, but doesn't review or approve the safety and science of these trials. The website is maintained by the National Library of Medicine (NLM). The links below go to the clinical trial information on clinicaltrials.gov. Talk with your health care professional about possible risks and benefits before joining any studies.
Wed, 2 Apr 2025 00:00:00 EDT
Conditions: Risk of Breast Cancer; Risk of Gynaecological Cancer; Risk of Colorectal Cancer; Risk of Upper Gastrointestinal Cancers; Risk of Hepatic Cancers; Risk of Lung Cancer; Risk of Skin Cancers Except Basal-cell Carcinomas; Risk of Head and Neck Cancers; Risk of Mesothelioma; Risk of Kidney Cancer; Risk of Prostate Cancer; Risk of Urothelial Cancers; Risk of Endocrine Cancers; Risk of Hematologic Malignancies; Risk of Several Cancer Types; Risk of Second Malignancy in Individuals Treated for a Childhood Cancer; Risk of Neoplasia
Interventions: Diagnostic Test: biological samples
Sponsors: Gustave Roussy, Cancer Campus, Grand Paris
Not yet recruiting
Tue, 25 Mar 2025 00:00:00 EDT
Conditions: Pretreated Pleural Mesothelioma
Interventions: Drug: Ivonescimab Combined With Chemotherapy
Sponsors: The First Hospital of Jilin University
Recruiting
Tue, 25 Mar 2025 00:00:00 EDT
Conditions: Pleural Mesothelioma; Pleural Diseases; Cancer; FAPI; Fibroblast Activation Protein Inhibitor
Interventions: Drug: [68Ga]Ga-FAPI-46 PET/CT
Sponsors: Aalborg University Hospital
Recruiting
Tue, 25 Mar 2025 00:00:00 EDT
Conditions: Solid Tumours; Sarcoma; Squamous NSCLC; Malignant Mesothelioma; HNSCC; Non Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma
Interventions: Drug: OKN4395; Combination Product: Pembrolizumab; Other: Fasting; Other: Fed
Sponsors: Epkin; Precision For Medicine
Recruiting
Tue, 25 Mar 2025 00:00:00 EDT
Conditions: Mesothelioma, Malignant Pleural
Sponsors: Fondazione IRCCS Policlinico San Matteo di Pavia; Istituti Clinici Scientifici Maugeri di Pavia
Recruiting
Tue, 25 Mar 2025 00:00:00 EDT
Conditions: Pleural Mesotheliomas
Interventions: Drug: Ivonescimab
Sponsors: Intergroupe Francophone de Cancerologie Thoracique; Summit Therapeutics
Not yet recruiting
Tue, 25 Mar 2025 00:00:00 EDT
Conditions: Mesothelin-Expressing Tumors; Epithelial Ovarian Cancer; Malignant Pleural Mesothelioma, Advanced; Malignant Peritoneal Mesothelioma, Advanced; Pancreatic Adenocarcinoma Advanced or Metastatic; Lung Adenocarcinoma Metastatic; Cholangiocarcinoma Advanced; Cholangiocarcinoma Non-resectable; Mesothelin-expressing Advanced Cancers; Mesothelin-positive Advanced Malignant Solid Tumors
Interventions: Drug: CT-95
Sponsors: Context Therapeutics Inc.
Recruiting
Tue, 25 Mar 2025 00:00:00 EDT
Conditions: Solid Tumor Cancer; Solid Tumor, Unspecified, Adult; Colorectal Carcinoma; Colorectal Carcinoma (CRC); Non Small Cell Lung Cancer; Small Cell Lung Cancer ( SCLC ); Pancreatic Cancer; NSCLC; Mesothelioma; Ovarian Cancer; Ovarian Carcinoma; Head and Neck (HNSCC); Head and Neck Cancer; Renal Cell Carcinoma (Kidney Cancer); Triple Negative Breast Cancer (TNBC)
Interventions: Other: No additional intervention administered in this long term follow-up study
Sponsors: A2 Biotherapeutics Inc.
Not yet recruiting
Tue, 25 Mar 2025 00:00:00 EDT
Conditions: Peritoneal Mesothelioma; Gestational Trophoblastic Tumor; Thymoma and Thymic Carcinoma; Anaplastic Thyroid Carcinomas; Gastroenteropancreatic Neuroendocrine Tumor; Carcinoid Tumor
Interventions: Drug: DOMVANALIMAB + ZIMBERELIMAB; Drug: DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4
Sponsors: Hospices Civils de Lyon
Not yet recruiting
Tue, 25 Mar 2025 00:00:00 EDT
Conditions: Mesothelioma; Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Ovarian Neoplasms; Lung Neoplasms; Thymus Neoplasms; Colonic Neoplasms
Interventions: Device: mesothelin expression testing; Biological: TNhYP217 CAR T Cells; Drug: fludarabine; Drug: cyclophosphamide
Sponsors: National Cancer Institute (NCI)
Not yet recruiting
Menu